Results 51 to 60 of about 17,566 (194)

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow

Haematologica, 2012
We investigated 15,542 patients with suspected BCR-ABL1- negative myeloproliferative or myelodysplastic/myeloproliferative neoplasm (including 359 chronic myelomonocytic leukemia) by a molecular marker set.
Susanne Schnittger, Ulrike Bacher, Christiane Eder, Frank Dicker, Tamara Alpermann, Vera Grossmann, Alexander Kohlmann, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach   +9 more
doaj   +1 more source

Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact

Cancer, Volume 132, Issue 11, 1 June 2026.
Abstract Background Mutations in cytokine receptor and JAK/STAT; Cy‐JAK/STAT) signaling genes drive myeloproliferative neoplasms (MPNs) but remain incompletely characterized in acute myeloid leukemia (AML). The authors evaluated the prevalence, clinical presentation, and prognostic significance of Cy‐JAK/STAT pathway mutations in patients with AML and ...
Moath Albliwi, Daniel P. Nurse, Emily C. Zabor, John Hanna, Jessica El‐Asmar, Ameed Bawwab, Hasan Abuamsha, Yomna Abu‐Farsakh, Heya Batah, Asad Rauf, Joy Nakitandwe, David S. Bosler, Prerana Bangalore Parthasarathy, Tyler Alban, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Sudipto Mukherjee, Anjali S. Advani, Hetty E. Carraway, Moaath K. Mustafa Ali   +22 more
wiley   +1 more source

Colorectal Liver Metastasis, Primary Gallbladder Carcinoma and Myelofibrosis Present Simultaneously in a Liver Resection Specimen

Case Reports in Gastroenterology, 2015
Myelofibrosis and gallbladder carcinoma are both very rare diseases. This case report describes a patient with a history of myelofibrosis and colorectal carcinoma who was diagnosed with colorectal liver metastases.
Sophie A. Gray, Menno H. Raber, Esther Provoost, Gert-Jan Toes, Joost M. Klaase   +4 more
doaj   +1 more source

Pacritinib Impact on QT Interval: Results of a Thorough QT Study and Post Hoc Analysis of Prospective Clinical Trial Data

Clinical Pharmacology in Drug Development, Volume 15, Issue 6, June 2026.
Abstract Pacritinib, an inhibitor of JAK2/IRAK1/ACVR1 that is devoid of JAK1 activity, approved for treating myelofibrosis in patients with severe thrombocytopenia, carries a label warning for QT interval prolongation. To evaluate the cardiac safety of pacritinib, a randomized, placebo‐ and active‐controlled, single‐dose thorough QT (TQT) study was ...
Sarah A. Buckley, Suliman Al‐Fayoumi, James P. Dean, Jessica Zhang, Purvi Suthar, Muriel Richard   +5 more
wiley   +1 more source

Oral Lesions Developed in Post‐Hematopoietic Stem Cell Transplant Patients and the Role of Cryogun Cryotherapy

Clinical and Experimental Dental Research, Volume 12, Issue 3, June 2026.
ABSTRACT Objective To investigate the development of oral premalignant and malignant lesions as a major long‐term complication following hematopoietic stem cell transplantation. Methods This single‐center retrospective study identified 17 patients who developed 26 pathology‐confirmed oral premalignant and malignant lesions after hematopoietic stem cell
Pei Hsuan Lu, Kelly Yi Ping Liu, Samson P. Ng, Catherine F. Poh   +3 more
wiley   +1 more source

Targeted Therapy of Myelofibrosis

Клиническая онкогематология, 2017
Background. Myelofibrosis (primary myelofibrosis, post-essential trombocythemia myelofibrosis, post-polycythemia myelofibrosis) is the most complex and pressing problem among all Ph-negative myeloproliferative diseases. The present article summarizes the
Ol’ga Yur’evna Vinogradova, V. A. Shuvaev, I. S. Martynkevich, M. M. Pankrashkina, M. S. Fominykh, E. V. Efremova, K. Yu. Krutikova, L. B. Polushkina, N. N. Sharkunov, S. V. Voloshin, A. V. Chechetkin   +10 more
doaj   +1 more source

A novel JAK1 variant in chronic eosinophilic leukaemia with response to benralizumab

British Journal of Haematology, EarlyView.
Isabel C. Vallecillo‐Viejo, Michael D. Claiborne, Charles F. Anderson, Samantha Shafer, Alan Saven, Bryce A. Seifert, Morgan Similuk, Magdalena Walkiewicz, Irina Maric, Pia R. Crespo, Lori Broderick, Andrew A. White, Amy D. Klion   +12 more
wiley   +1 more source

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

Haematologica, 2014
Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reaction, fragment-sizing ...
Hajnalka Andrikovics, Tunde Krahling, Katalin Balassa, Gabriella Halm, Andras Bors, Magdalena Koszarska, Arpad Batai, Janos Dolgos, Judit Csomor, Miklos Egyed, Andrea Sipos, Peter Remenyi, Attila Tordai, Tamas Masszi   +13 more
doaj   +1 more source

Platelet-derived growth factor receptor β activation and regulation in murine myelofibrosis

Haematologica, 2020
There is prevailing evidence to suggest a decisive role for platelet-derived growth factors (PDGF) and their receptors in primary myelofibrosis. While PDGF receptor β (PDGFRβ) expression is increased in bone marrow stromal cells of patients correlating ...
Frederike Kramer, Jens Dernedde, Artur Mezheyeuski, Rudolf Tauber, Patrick Micke, Kai Kappert   +5 more
doaj   +1 more source

Fibrocytes in primary myelofibrosis

Oncotarget, 2021
Shimoda, Kazuya, Ozono, Yoshinori, Shide, Kotaro   +2 more
openaire   +2 more sources